Disclosure: Prof Dr Axel Dignass has received grants/research support from the Institut für Gemeinwohl and Stiftung Leben mit Krebs, and honoraria or consultation fees from AbbVie, MSD, Ferring, Roche/Genentech, Takeda, Pharmacosmos, Holystone Biotech, Falk, Mundipharma, Toray, Allergosan, Hospira, Robarts, TFS Trial Support, and Sandoz/Hexal. He has participated in company-sponsored speaker’s ...